---
title: 'In the era of Bortezomib-based Induction, intensification of Melphalan-based
  conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed
  Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT'
date: '2024-01-31'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38297040/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240201170635&v=2.18.0
source: heidelberg[Affiliation]
description: Bortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised
  to intensify conditioning in autologous hematopoietic stem cell transplantation
  (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel
  with Mel200 during upfront AHCT. Between 2010 and 2017, MM patients who received
  Vel-Mel (n = 292) conditioning were compared with 4,096 Mel200 patients in the same
  58 centres. Pre-AHCT, compared to Mel200 patients, Vel-Mel patients had similar
  ...
disable_comments: true
---
Bortezomib (Vel)- Melphalan 200 mg/m2 (Mel200) (Vel-Mel) has been utilised to intensify conditioning in autologous hematopoietic stem cell transplantation (AHCT) for multiple myeloma (MM). This EBMT registry-based study compared Vel-Mel with Mel200 during upfront AHCT. Between 2010 and 2017, MM patients who received Vel-Mel (n = 292) conditioning were compared with 4,096 Mel200 patients in the same 58 centres. Pre-AHCT, compared to Mel200 patients, Vel-Mel patients had similar ...